Business
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the ongoing Phase 1b clinical trial in Alzheimer's disease (AD).PRECISE-AD Phase 1b trial is fully enrolled and progressing on schedule, with the blinded 6-month interim analysis anticipated in early Q3 2026 and 12-month top-line data anticipated in early 2027. The pla
About this update from Promis Neurosciences Inc.
[{"type":"image","alt":"ProMIS Neurosciences Inc.","displaySize":"","headline":null,"caption":"ProMIS Neurosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/cda799201650b516b39828de8c76948b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oYrAgVTxC0OnTyq_NUY5Dg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NQ--/https://media.zenfs.com/en/globenewswire.com/cda799201650b516b39828de8c76948b","width":300,"height":125},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/oYrAgVTxC0OnTyq_NUY5Dg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NQ--/https://media.zenfs.com/en/globenewswire.com/cda799201650b516b39828de8c76948b","width":300,"height":125}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the ongoing Phase 1b clinical trial in Alzheimer's disease (AD).","length":299,"tagName":"p"}]},{"val":[{"type":"text","content":"PRECISE-AD Phase 1b trial is fully enrolled and progressing on schedule, with the blinded 6-month interim analysis anticipated in early Q3 2026 and 12-month top-line data anticipated in early 2027. ","length":197,"tagName":"p"}]},{"val":[{"type":"text","content":"The planned interim analysis is expected to include a qualitative assessment of aggregated safety data, including amyloid-related imaging abnormalities (ARIA) incidence, as well as key biomarker trends across all study participants at the 6-month timepoint.","length":257,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":753,"olType":false},{"type":"text","content":"Cambridge, Massachusetts, May 12, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update.","length":380,"tagName":"p"},{"type":"text","content":""2026 has the potential to be a significant year for patients with Alzheimer's disease and their caregivers,” said Neil ...